<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265276</url>
  </required_header>
  <id_info>
    <org_study_id>ENDO/2014/4</org_study_id>
    <nct_id>NCT02265276</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease</brief_title>
  <acronym>GLAZED</acronym>
  <official_title>A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease (GLAZED Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Command Hospital, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Command Hospital, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non Alcoholic Fatty Liver Disease (NAFLD) is considered as the component of metabolic
      syndrome. The prevalence of the same has been increasing rapidly in India, along with an
      increase in the prevalence of diabetes and obesity. Insulin resistance is the key underlying
      pathogenetic mechanism of NAFLD. NAFLD accounts for significant morbidity and mortality and
      the therapeutic options are limited. Insulin sensitizing drugs are used in the management of
      NAFLD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The therapeutic options for the management of nonalcoholic fatty liver disease (NAFLD)
      include lifestyle modifications, insulin sensitizers, vitamin E, antioxidants and
      cytoprotective agents. Glitazones are insulin sensitizing drugs and act by stimulating the
      PPAR gamma receptors. The drugs like Pioglitazone and Rosiglitazone have shown conflicting
      results in the NAFLD trials. Dual PPAR stimulators (PPAR gamma and PPAR alfa) are known as
      the &quot;Glitazars&quot; and are useful in simultaneously controlling the hyperglycemia, dyslipidemia
      and insulin resistance. Saroglitazar is the first drug approved in the investigators country
      for the management of diabetic dyslipidemia. The investigators plan to study the efficacy of
      this drug in comparison to Pioglitazone in patients of NAFLD over a period of 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the NAFLD fibrosis score</measure>
    <time_frame>At baseline and the end of 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body composition</measure>
    <time_frame>At baseline and the end of 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin resistance</measure>
    <time_frame>At baseline and the end of 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid profile</measure>
    <time_frame>At baseline and the end of 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>At baseline and the end of 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Saroglitazar Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tab Saroglitazar 4 mg oral daily fixed dose for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tab Pioglitazone 30 mg daily fixed dose for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar</intervention_name>
    <description>Tab Saroglitazar 4 mg oral daily for 24 weeks</description>
    <arm_group_label>Saroglitazar Group</arm_group_label>
    <other_name>Glitazar group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Tab Pioglitazone 30 mg oral daily for 24 weeks</description>
    <arm_group_label>Pioglitazone Group</arm_group_label>
    <other_name>Placebo Comparator group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Drug naive patients with NAFLD diagnosed on ultrasonography, BMI &gt; 23 kg/m2 and ALT &gt;
             1.5 times the upper limit of normal

        Exclusion Criteria:

          -  Use of any drugs other than lifestyle modification for NAFLD, HbA1c &gt; 8% FBS&gt;200,
             Bilirubin &gt; 1.5 mg/dL

          -  Any illness likely to cause transaminitis and positive viral markers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hari Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Command Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hari Kumar, MD</last_name>
    <phone>00918146141700</phone>
    <email>hariendo@rediffmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Command Hospital</name>
      <address>
        <city>Panchkula</city>
        <state>Haryana</state>
        <zip>134107</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JBS Yadava</last_name>
      <phone>00911722867534</phone>
      <email>hariendo@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Command Hospital, India</investigator_affiliation>
    <investigator_full_name>Hari Kumar</investigator_full_name>
    <investigator_title>Endocrinologist</investigator_title>
  </responsible_party>
  <keyword>NAFLD, Diabetes, Glitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

